MedTrace Logo

AUGMENTED RESPONSE OF VOLATILE BIOMARKERS IN THE ASSESSMENT OF OESOPHAGOGASTRIC CANCER (AROMA2)

NCT07260734 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 6000

Last updated 2025-12-03

No results posted yet for this study

Summary

Cancer of the stomach and oesophagus is among the world's top five cancers. Survival rates are very poor as the disease presents late and early symptoms are non-specific. The study team has developed a non-invasive test for cancers of the stomach and oesophagus based on the detection of volatile organic compounds in exhaled breath. These compounds are known to be produced by both cancers as well as cancer associated bacteria within the gut.

The proposed innovation is to improve the accuracy of this test by investigating whether simple metabolic substrates can increase the production of these volatile organic compounds by both the tumour and its associated bacteria.

Conditions

  • OESOPHAGO-GASTRIC CARCINOMA
  • Oesophageal Adenocarcinoma
  • Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma
  • Oesophageal Cancer Nos
  • Oesophageal Cancer
  • Oesophageal Junction Cancer
  • Breath Tests
  • Volatile Organic Compound

Interventions

DIAGNOSTIC_TEST

Breath Test

Diagnostic Test: Breath test Participants must be fasted for a minimum of six hours prior to breath sample collection. Breath samples will be collected prior to the reference test for each participant. Participants will then be asked to consume an Oral Stimulant Drink (OSD). The oral stimulant drink (120ml) will be composed of 25g glucose, 25g glycerol, 0.6g iron sulphate, 1.2g of "Thicken Up" thickener and combined amino acids (0.08g tyrosine, 1.8g phenylalanine, 2.1g glutamic acid). Diagnostic Test: Augmented breath test: Participants will then be asked to repeat a breath sample 15 minutes after consumption of the OSD.

Sponsors & Collaborators

  • Imperial College London

    lead OTHER

Principal Investigators

  • George Hanna · Imperial College London

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-12-01
Primary Completion
2028-11-01
Completion
2028-11-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07260734 on ClinicalTrials.gov